Dihydroartemisinin attenuates osteoclast formation and bone resorption via inhibiting the NF‑κB, MAPK and NFATc1 signaling pathways and alleviates osteoarthritis

Ding,Dong; Yan,Jiangbo; Feng,Gangning; Zhou,Yong; Ma,Long; Jin,Qunhua

doi:10.3892/ijmm.2021.5059

January-2022 Volume 49 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2022 Volume 49 Issue 1

Full Size Image

Article Open Access

Dihydroartemisinin attenuates osteoclast formation and bone resorption via inhibiting the NF‑κB, MAPK and NFATc1 signaling pathways and alleviates osteoarthritis

Authors:
- Dong Ding
- Jiangbo Yan
- Gangning Feng
- Yong Zhou
- Long Ma
- Qunhua Jin
View Affiliations / Copyright

Affiliations: Ningxia Medical University, The General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China, Orthopedics Ward 3, The General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China

Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 4
|
Published online on: November 3, 2021

https://doi.org/10.3892/ijmm.2021.5059
Expand metrics +

Abstract

Osteoarthritis (OA) is a chronic, progressive and degenerative disease, and its incidence is increasing on a yearly basis. However, the pathological mechanism of OA at each stage is still unclear. The present study aimed to explore the underlying mechanism of dihydroartemisinin (DHA) in terms of its ability to inhibit osteoclast activation, and to determine its effects on OA in rats. Bone marrow‑derived macrophages were isolated as osteoclast precursors. In the presence or absence of DHA, osteoclast formation was assessed by tartrate‑resistant acid phosphatase (TRAP) staining, cell viability was assessed by Cell Counting Kit‑8 assay, the presence of F‑actin rings was assessed by immunofluorescence, bone resorption was determined by bone slices, luciferase activities of NF‑κB and nuclear factor of activated T cell cytoplasmic 1 (NFATc1) were determined using luciferase assay kits, the protein levels of biomolecules associated with the NF‑κB, MAPK and NFATc1 signaling pathways were determined using western blotting, and the expression of genes involved in osteoclastogenesis were measured using reverse transcription‑quantitative PCR. A knee OA rat model was designed by destabilizing the medial meniscus (DMM). A total of 36 rats were assigned to three groups, namely the sham‑operated, DMM + vehicle and DMM + DHA groups, and the rats were administered DHA or DMSO. At 4 and 8 weeks postoperatively, the microarchitecture of the subchondral bone was analyzed using micro‑CT, the thickness of the cartilage layers was calculated using H&E staining, the extent of cartilage degeneration was scored using Safranin O‑Fast Green staining, TRAP‑stained osteoclasts were counted, and the levels of receptor activator of NF‑κB ligand (RANKL), C‑X‑C‑motif chemokine ligand 12 (CXCL12) and NFATc1 were measured using immunohistochemistry. DHA was found to inhibit osteoclast formation without cytotoxicity, and furthermore, it did not affect bone formation. In addition, DHA suppressed the expression levels of NF‑κB, MAPK, NFATc1 and genes involved in osteoclastogenesis. Progressive cartilage loss was observed at 8 weeks postoperatively. Subchondral bone remodeling was found to be dominated by bone resorption accompanied by increases in the levels of RANKL, CXCL12 and NFATc1 during the first 4 weeks. DHA was found to delay OA progression by inhibiting osteoclast formation and bone resorption during the early phase of OA. Taken together, the results of the present study demonstrated that the mechanism through which DHA could inhibit osteoclast activation may be associated with the NF‑κB, MAPK and NFATc1 signaling pathways, thereby indicating a potential novel strategy for OA treatment.

View Figures

View References

1	Driban JB, Harkey MS, Barbe MF, Ward RJ, MacKay JW, Davis JE, Lu B, Price LL, Eaton CB, Lo GH and McAlindon TE: Risk factors and the natural history of accelerated knee osteoarthritis: A narrative review. Bmc Musculoskel Dis. 21:3322020. View Article : Google Scholar
2	GBD 2017 Disease and Injury Incidence and Prevalence Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. Lancet. 392:1789–1858. 2018. View Article : Google Scholar
3	Bruyère O, Cooper C, Arden N, Branco J, Brandi ML, Herrero-Beaumont G, Berenbaum F, Dennison E, Devogelaer JP, Hochberg M, et al: Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. Drug Aging. 32:179–187. 2015. View Article : Google Scholar
4	Goldring SR and Goldring MB: Changes in the osteochondral unit during osteoarthritis: Tructure, function and cartilage-bone crosstalk. Nat Rev Rheumatol. 12:632–644. 2016. View Article : Google Scholar : PubMed/NCBI
5	Zhu X, Chan YT, Yung PSH, Tuan RS and Jiang Y: Subchondral bone remodeling: A therapeutic target for osteoarthritis. Front Cell Dev Biol. 8:6077642021. View Article : Google Scholar : PubMed/NCBI
6	Li G, Ma Y, Cheng TS, Landao-Bassonga E, Qin A, Pavlos NJ, Zhang C, Zheng Q and Zheng MH: Identical subchondral bone microarchitecture pattern with increased bone resorption in rheumatoid arthritis as compared to osteoarthritis. Osteoarthr Cartilage. 22:2083–2092. 2014. View Article : Google Scholar
7	Lin C, Liu L, Zeng C, Cui ZK, Chen Y, Lai P, Wang H, Shao Y, Zhang H, Zhang R, et al: Activation of mTORC1 in subchondral bone preosteoblasts promotes osteoarthritis by stimulating bone sclerosis and secretion of CXCL12. Bone Res. 7:52019. View Article : Google Scholar : PubMed/NCBI
8	Cui Z, Xu C, Li X, Song J and Yu B: Treatment with recombinant lubricin attenuates osteoarthritis by positive feedback loop between articular cartilage and subchondral bone in ovariectomized rats. Bone. 74:37–47. 2015. View Article : Google Scholar : PubMed/NCBI
9	Khorasani MS, Diko S, Hsia AW, Anderson MJ, Genetos DC, Haudenschild DR and Christiansen BA: Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice. Arthritis Res Ther. 17:302015. View Article : Google Scholar : PubMed/NCBI
10	Pereira M, Petretto E, Gordon S, Bassett J, Williams GR and Behmoaras J: Common signalling pathways in macrophage and osteoclast multinucleation. J Cell Sci. 131:jcs2162672018. View Article : Google Scholar : PubMed/NCBI
11	Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
12	Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397:315–323. 1999. View Article : Google Scholar : PubMed/NCBI
13	Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:3597–3602. 1998. View Article : Google Scholar : PubMed/NCBI
14	Yang X, Liang J, Wang Z, Su Y, Zhou B, Wu Z, Li J, Li X, Chen R, Zhao J, et al: Sesamolin protects mice from ovariectomized bone loss by inhibiting osteoclastogenesis and RANKL-mediated NF-κB and MAPK signaling pathways. Front Pharmacol. 12:6646972021. View Article : Google Scholar
15	Zou W and Teitelbaum SL: Integrins, growth factors, and the osteoclast cytoskeleton. Ann Ny Acad Sci. 1192:27–31. 2010. View Article : Google Scholar : PubMed/NCBI
16	Lian WS, Ko JY, Chen YS, Ke HJ, Hsieh CK, Kuo CW, Wang SY, Huang BW, Tseng JG and Wang FS: MicroRNA-29a represses osteoclast formation and protects against osteoporosis by regulating PCAF-mediated RANKL and CXCL12. Cell Death Dis. 10:7052019. View Article : Google Scholar : PubMed/NCBI
17	Wang X, Yamauchi K and Mitsunaga T: A review on osteoclast diseases and osteoclastogenesis inhibitors recently developed from natural resources. Fitoterapia. 142:1044822020. View Article : Google Scholar : PubMed/NCBI
18	Tu Y: The development of new antimalarial drugs: Qinghaosu and dihydro-qinghaosu. Chin Med J (Engl). 112:976–977. 1999.
19	Wartenberg M, Wolf S, Budde P, Grünheck F, Acker H, Hescheler J, Wartenberg G and Sauer H: The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. Lab Invest. 83:1647–1655. 2003. View Article : Google Scholar : PubMed/NCBI
20	Hwang YP, Yun HJ, Kim HG, Han EH, Lee GW and Jeong HG: Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms. Biochem Pharmacol. 79:1714–1726. 2010. View Article : Google Scholar : PubMed/NCBI
21	Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, Lin LP and Ding J: Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol Ther. 7:1017–1023. 2008. View Article : Google Scholar : PubMed/NCBI
22	Xu H, He Y, Yang X, Liang L, Zhan Z, Ye Y, Yang X, Lian F and Sun L: Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford). 46:920–926. 2007. View Article : Google Scholar
23	Dong YJ, Li WD and Tu YY: Effect of dihydro-qinghaosu on auto-antibody production, TNF alpha secretion and pathologic change of lupus nephritis in BXSB mice. Zhongguo Zhong Xi Yi Jie He Za Zhi. 23:676–679. 2003.In Chinese. PubMed/NCBI
24	Feng MX, Hong JX, Wang Q, Fan YY, Yuan CT, Lei XH, Zhu M, Qin A, Chen HX and Hong D: Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts. Sci Rep. 6:190742016. View Article : Google Scholar : PubMed/NCBI
25	Li WD, Dong YJ, Tu YY and Lin ZB: Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation. Int Immunopharmacol. 6:1243–1250. 2006. View Article : Google Scholar : PubMed/NCBI
26	Zhou L, Liu Q, Yang M, Wang T, Yao J, Cheng J, Yuan J, Lin X, Zhao J, Tickner J and Xu J: Dihydroartemisinin, an anti-malaria drug, suppresses estrogen deficiency-induced osteoporosis, osteoclast formation, and RANKL-induced signaling pathways. J Bone Miner Res. 31:964–974. 2016. View Article : Google Scholar
27	Hu JP, Nishishita K, Sakai E, Yoshida H, Kato Y, Tsukuba T and Okamoto K: Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways. Eur J Pharmacol. 580:70–79. 2008. View Article : Google Scholar
28	Ryoo GH, Moon YJ, Choi S, Bae EJ, Ryu JH and Park BH: Tussilagone promotes osteoclast apoptosis and prevents estrogen deficiency-induced osteoporosis in mice. Biochem Biophys Res Commun. 531:508–514. 2020. View Article : Google Scholar : PubMed/NCBI
29	Würger T, Roschger P, Zwettler E, Fratzl P, Rogers MJ, Klaushofer K and Rumpler M: Osteoclasts on bone and dentin in vitro: Mechanism of degradation and comparison of resorption behaviour. Bone. 51:S92012. View Article : Google Scholar
30	Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH and Xu J: 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. J Bone Miner Res. 18:2159–2168. 2003. View Article : Google Scholar : PubMed/NCBI
31	Kwak SC, Cheon YH, Lee CH, Jun HY, Yoon KH, Lee MS and Kim JY: Grape seed proanthocyanidin extract prevents bone loss via regulation of osteoclast differentiation, apoptosis, and proliferation. Nutrients. 12:31642020. View Article : Google Scholar :
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
33	Glasson SS, Blanchet TJ and Morris EA: The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthr Cartilage. 15:1061–1069. 2007. View Article : Google Scholar
34	Zhao YG, Wang Y, Guo Z, Gu AD, Dan HC, Baldwin AS, Hao W and Wan YY: Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway. J Immunol. 189:4417–4425. 2012. View Article : Google Scholar : PubMed/NCBI
35	National Research Council (US) Committee for the Update of the Guide for the Care and use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. 8th edition. National Academies Press (US); Washington, DC: 2011
36	Bei M, Tian F, Liu N, Zheng Z, Cao X, Zhang H, Wang Y, Xiao Y, Dai M and Zhang L: A novel rat model of patellofemoral osteoarthritis due to patella baja, or low-lying patella. Med Sci Monit. 25:2702–2717. 2019. View Article : Google Scholar : PubMed/NCBI
37	Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC, Askin FB, Frassica FJ, Chang W, Yao J, et al: Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med. 19:704–712. 2013. View Article : Google Scholar : PubMed/NCBI
38	Moskowitz RW: Osteoarthritis cartilage histopathology: Grading and staging. Osteoarthr Cartilage. 14:1–2. 2006. View Article : Google Scholar
39	Zhu S, Zhu J, Zhen G, Hu Y, An S, Li Y, Zheng Q, Chen Z, Yang Y, Wan M, et al: Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. J Clin Invest. 129:1076–1093. 2019. View Article : Google Scholar :
40	Simon D, Derer A, Andes FT, Lezuo P, Bozec A, Schett G, Herrmann M and Harre U: Galectin-3 as a novel regulator of osteoblast-osteoclast interaction and bone homeostasis. Bone. 105:35–41. 2017. View Article : Google Scholar : PubMed/NCBI
41	Zhang J, Cai L, Tang L, Zhang X, Yang L, Zheng K, He A, Boccaccini AR, Wei J and Zhao J: Highly dispersed lithium doped mesoporous silica nanospheres regulating adhesion, proliferation, morphology, ALP activity and osteogenesis related gene expressions of BMSCs. Colloids Surf B Biointerfaces. 170:563–571. 2018. View Article : Google Scholar : PubMed/NCBI
42	Kang MR, Jo SA, Yoon YD, Park KH, Oh SJ, Yun J, Lee CW, Nam KH, Kim Y, Han SB, et al: Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB. Mar Drugs. 12:5643–5656. 2014. View Article : Google Scholar : PubMed/NCBI
43	Cai G, Aitken D, Laslett LL, Pelletier JP, Martel-Pelletier J, Hill C, March L, Wluka AE, Wang Y, Antony B, et al: Effect of intravenous zoledronic acid on tibiofemoral cartilage volume among patients with knee osteoarthritis with bone marrow lesions: A randomized clinical trial. JAMA. 323:1456–1466. 2020. View Article : Google Scholar : PubMed/NCBI
44	Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H, Sone T, Taguchi A, Tanaka S, Ohashi M, et al: Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: Two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study). Osteoporosis Int. 28:389–398. 2017. View Article : Google Scholar
45	Wu GS, Lu JJ, Guo JJ, Huang MQ, Gan L, Chen XP and Wang YT: Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells. Pharmacol Rep. 65:453–459. 2013. View Article : Google Scholar : PubMed/NCBI
46	Crockett JC, Rogers MJ, Coxon FP, Hocking LJ and Helfrich MH: Bone remodelling at a glance. J Cell Sci. 124:991–998. 2011. View Article : Google Scholar : PubMed/NCBI
47	L Fvall H, Newbould H, Karsdal MA, Dziegiel MH, Richter J, Henriksen K and Thudium CS: Osteoclasts degrade bone and cartilage knee joint compartments through different resorption processes. Arthritis Res Ther. 20:672018. View Article : Google Scholar
48	Luo T, Liu H, Feng W, Liu D, Du J, Sun J, Wang W, Han X, Guo J, Amizuka N, et al: Adipocytes enhance expression of osteoclast adhesion-related molecules through the CXCL12/CXCR4 signalling pathway. Cell Prolif. 50:e123172017. View Article : Google Scholar
49	Tran MT, Okusha Y, Feng Y, Morimatsu M, Wei P, Sogawa C, Eguchi T, Kadowaki T, Sakai E, Okamura H, et al: The inhibitory role of Rab11b in osteoclastogenesis through triggering lysosome-induced degradation of c-Fms and RANK surface receptors. Int J Mol Sci. 21:93522020. View Article : Google Scholar :
50	Kimachi K, Kajiya H, Nakayama S, Ikebe T and Okabe K: Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis. Naunyn Schmiedebergs Arch Pharmacol. 383:297–308. 2011. View Article : Google Scholar : PubMed/NCBI
51	Liu W and Zhang X: Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review). Mol Med Rep. 11:3212–3218. 2015. View Article : Google Scholar : PubMed/NCBI
52	Zhao XL, Chen JJ, Si SY, Chen LF and Zhen W: T63 inhibits osteoclast differentiation through regulating MAPKs and Akt signaling pathways. Eur J Pharmacol. 834:30–35. 2018. View Article : Google Scholar : PubMed/NCBI
53	Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S and Inoue J: Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J. 20:1271–1280. 2001. View Article : Google Scholar : PubMed/NCBI
54	Fang C, He M, Li D and Xu Q: YTHDF2 mediates LPS-induced osteoclastogenesis and inflammatory response via the NF-κB and MAPK signaling pathways. Cell Signal. 85:1100602021. View Article : Google Scholar
55	Iijima H, Aoyama T, Tajino J, Ito A, Nagai M, Yamaguchi S, Zhang X, Kiyan W and Kuroki H: Subchondral plate porosity colocalizes with the point of mechanical load during ambulation in a rat knee model of post-traumatic osteoarthritis. Osteoarthritis Cartilage. 24:354–363. 2016. View Article : Google Scholar
56	Findlay DM and Kuliwaba JS: Bone-cartilage crosstalk: A conversation for understanding osteoarthritis. Bone Res. 4:160282016. View Article : Google Scholar : PubMed/NCBI
57	Sanchez C, Deberg MA, Piccardi N, Msika P, Reginster JY and Henrotin YE: Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by inter-leukin-6, -1beta and oncostatin M pre-treated non-sclerotic osteoblasts. Osteoarthritis Cartilage. 13:979–987. 2005. View Article : Google Scholar : PubMed/NCBI
58	Priam S, Bougault C, Houard X, Gosset M, Salvat C, Berenbaum F and Jacques C: Identification of soluble 14-3-3ε as a novel subchondral bone mediator involved in cartilage degradation in osteoarthritis. Arthritis Rheum. 65:1831–1842. 2013. View Article : Google Scholar : PubMed/NCBI
59	Dou C, Zhang C, Kang F, Yang X, Jiang H, Bai Y, Xiang J, Xu J and Dong S: MiR-7b directly targets DC-STAMP causing suppression of NFATc1 and c-Fos signaling during osteoclast fusion and differentiation. Biochim Biophys Acta. 1839:1084–1096. 2014. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Dihydroartemisinin attenuates osteoclast formation and bone resorption via inhibiting the NF‑κB, MAPK and NFATc1 signaling pathways and alleviates osteoarthritis

This article is mentioned in:

Abstract

Related Articles